All articles tagged with #radioligand therapy
Novartis announced that its drug Pluvicto showed significant benefits in delaying disease progression in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, based on interim results from the Phase III PSMAddition trial, and plans to submit for regulatory review after presenting the data.
Novartis presented data from the Phase III NETTER-2 trial at the 2024 ASCO Gastrointestinal Cancers Symposium, showing that Lutathera plus octreotide LAR significantly reduced the risk of disease progression or death by 72% as a first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study confirmed the clinical benefit of first-line radioligand therapy for newly diagnosed patients with advanced GEP-NETs, addressing a significant unmet need. The trial is ongoing for further evaluation of secondary endpoints including overall survival and long-term safety.
Eli Lilly and Co has announced its acquisition of Point Biopharma Global for $1.4 billion, gaining access to targeted cancer therapies. The deal will provide Lilly with experimental therapies that combine radioactive particles with molecules that attach themselves to tumors. Point Biopharma is currently testing these therapies in late-stage studies. The acquisition is part of Lilly's strategy to bolster its pipeline amid competition for its cancer therapy Alimta. The deal is not expected to face regulatory hurdles, and Lilly will also gain access to Point Biopharma's manufacturing plant for radiopharmaceuticals.
Novartis announced that its radioligand therapy Lutathera, in combination with long-acting octreotide, demonstrated a statistically significant improvement in progression-free survival (PFS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Phase III clinical trial. The trial met its primary endpoint of improved PFS and a key secondary endpoint of objective response rate. Lutathera is the first radioligand therapy to show clinically meaningful benefit in a first-line setting. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities. Novartis is also exploring the use of radioligand therapies in other advanced cancers and expanding its manufacturing capabilities to meet the increasing demand.